Publicaciones en colaboración con investigadores/as de Imperial College London (19)

2022

  1. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease

    Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220

  2. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis

    Movement Disorders, Vol. 37, Núm. 5, pp. 1028-1039

2021

  1. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 2, pp. 324-333

  2. Dissociable effects of age and Parkinson's disease on instruction-based learning

    Brain Communications, Vol. 3, Núm. 3

  3. Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease

    Journal of Neural Transmission, Vol. 128, Núm. 1, pp. 15-25

  4. Is chelation therapy a potential treatment for parkinson’s disease?

    International Journal of Molecular Sciences, Vol. 22, Núm. 7

  5. Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patients

    Parkinsonism and Related Disorders, Vol. 87, pp. 61-69

2020

  1. Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's disease

    NeuroImage: Clinical, Vol. 28

2019

  1. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, pp. 301-309

  2. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system

    Brain, Vol. 142, Núm. 7, pp. 2023-2036

2018

  1. 11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

    Movement Disorders, Vol. 33, Núm. 1, pp. 117-127

  2. Patterns of grey matter loss associated with motor subscores in early Parkinson's disease

    NeuroImage: Clinical, Vol. 17, pp. 498-504

2017

  1. Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review

    Neurological Sciences, Vol. 38, Núm. 12, pp. 2095-2101

  2. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility

    European Journal of Neurology, Vol. 24, Núm. 2, pp. 357-365

  3. Neuromelanin in parkinsonian disorders: an update

    International Journal of Neuroscience, Vol. 127, Núm. 12, pp. 1116-1123

  4. Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: The N3 i PD study (nigrosomal i ron i maging i n Parkinson's disease)

    BMJ Open, Vol. 7, Núm. 12

2016

  1. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

    Science Translational Medicine, Vol. 8, Núm. 341

2015

  1. Decoding brain state transitions in the pedunculopontine nucleus: Cooperative phasic and tonic mechanisms

    Frontiers in Neural Circuits, Vol. 9, Núm. OCTOBER, pp. 1-16

  2. Other Hypokinetic Parkinsonian Syndromes

    Brain Mapping: An Encyclopedic Reference (Elsevier Inc.), pp. 731-736